ReviewNature reviews. Rheumatology2020
IgG4-related disease: an update on pathophysiology and implications for clinical care.
Review in Nature reviews. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 207 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
207 citing papers in PubMed, 393 citations in OpenAlex.
- Inflammaging reshapes the immune ecosystem in IgG4-related dacryoadenitis and sialadenitis.Rheumatology (Oxford, England) · 2026Article
- IgG4-related disease in gastroenterology: from pathogenesis to clinical management and long-term outcomes.Journal of gastroenterology · 2026Review
- A case report: an unusual case of ulcerative intestinal IgG4-related disease with clinical features overlapping with probable intestinal Behcet's disease.BMC gastroenterology · 2026Article
- Giant paratesticular immunoglobulin G4-related disease mimicking malignancy: A case report.Urology case reports · 2026Article
- Inflammatory Aortopathies in Rheumatic Diseases: A State-of-the-Art Review.Diagnostics (Basel, Switzerland) · 2026Review
- IgG4-Related Kidney Disease and IgG4-Related Retroperitoneal Fibrosis: An Update on Diagnosis and Treatment.Kidney international reports · 2026Review
- Association of Th2-like inflammation with Tfh/Tph-germinal center immune programmes in submandibular gland lesions of IgG4-related disease.Rheumatology (Oxford, England) · 2026Article
- IgG4-Related Hepatic Disease Unmasking Hepatic Actinomycosis.Journal of clinical immunology · 2026Article
- Acute and chronic kidney injury following COVID-19 infection and vaccination: a narrative review.European journal of translational myology · 2026Article
- IgG4-related disease has a specific intestinal microbiota signature.EBioMedicine · 2026Article
- Proptosis Revealing a Neurological Form of IgG4-Related Disease: A Case Report and Literature Review.Cureus · 2026Article
- Complementary roles of 68Ga-FAPI and 18 F-FDG PET/CT in evaluating IgG4-related disease: a systematic review and pooled analysis.EJNMMI research · 2026Review
- Mikulicz Disease Revealing IgG4-Related Tubulointerstitial Nephritis: A Case Report and Literature Review.Reports (MDPI) · 2026Article
- Complete Treatment Response of Isolated Lacrimal IgG4-Related Disease onMolecular imaging and radionuclide therapy · 2026Article
- Spontaneously Resolving Pancreatic IgG4-Related Disease Representing With Systemic Involvement and Membranous Nephropathy.Kidney medicine · 2026Article
- Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases.Diabetes, obesity & metabolism · 2026Article
- Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial.Rheumatology and therapy · 2026Article
- Immunoglobulin G4-related Disease with Solitary Nasopharynx Involvement Mimicking Nasopharyngeal Tumor.Internal medicine (Tokyo, Japan) · 2026Article
- Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications.Diagnostics (Basel, Switzerland) · 2026Review
- Recurrent IgG4 Disease-Related Tubulointerstitial Nephritis Treated With Rituximab As Maintenance Therapy.Cureus · 2026Article
147 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
IgG4-related disease (IgG4-RD) has only existed as a unique disease entity since 2003, yet remarkable progress has already been achieved in describing the essential features of the disease. A framework for systematic clinical studies has been created by the development of a quantitative disease activity tool (the IgG4-RD Responder Index) and the validation of classification criteria, both of which were the products of international, multi-centre investigations. In addition, substantial strides have been made in understanding the pathophysiology of IgG4-RD. In particular, the central role of B cells in the disease has been demonstrated by both the robust clinical responsiveness of IgG4-RD to B cell depletion and by the identification of multiple self-antigens that promote B cell expansion. CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.